Literature DB >> 20924112

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

Norman Chan1, Isabel M Pires, Zuzana Bencokova, Carla Coackley, Kaisa R Luoto, Nirmal Bhogal, Minalini Lakshman, Ponnari Gottipati, F Javier Oliver, Thomas Helleday, Ester M Hammond, Robert G Bristow.   

Abstract

Acute and chronic hypoxia exists within the three-dimensional microenvironment of solid tumors and drives therapy resistance, genetic instability, and metastasis. Replicating cells exposed to either severe acute hypoxia (16 hours with 0.02% O(2)) followed by reoxygenation or moderate chronic hypoxia (72 hours with 0.2% O(2)) treatments have decreased homologous recombination (HR) protein expression and function. As HR defects are synthetically lethal with poly(ADP-ribose) polymerase 1 (PARP1) inhibition, we evaluated the sensitivity of repair-defective hypoxic cells to PARP inhibition. Although PARP inhibition itself did not affect HR expression or function, we observed increased clonogenic killing in HR-deficient hypoxic cells following chemical inhibition of PARP1. This effect was partially reversible by RAD51 overexpression. PARP1(-/-) murine embryonic fibroblasts (MEF) showed a proliferative disadvantage under hypoxic gassing when compared with PARP1(+/+) MEFs. PARP-inhibited hypoxic cells accumulated γH2AX and 53BP1 foci as a consequence of altered DNA replication firing during S phase-specific cell killing. In support of this proposed mode of action, PARP inhibitor-treated xenografts displayed increased γH2AX and cleaved caspase-3 expression in RAD51-deficient hypoxic subregions in vivo, which was associated with decreased ex vivo clonogenic survival following experimental radiotherapy. This is the first report of selective cell killing of HR-defective hypoxic cells in vivo as a consequence of microenvironment-mediated "contextual synthetic lethality." As all solid tumors contain aggressive hypoxic cells, this may broaden the clinical utility of PARP and DNA repair inhibition, either alone or in combination with radiotherapy and chemotherapy, even in tumor cells lacking synthetically lethal, genetic mutations. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924112      PMCID: PMC2978949          DOI: 10.1158/0008-5472.CAN-10-2352

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia.

Authors:  R S Bindra; P M Glazer
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

2.  ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Authors:  Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

3.  PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress.

Authors:  Rubén Martínez-Romero; Esther Martínez-Lara; Rocío Aguilar-Quesada; Andreína Peralta; F Javier Oliver; Eva Siles
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

4.  In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

Authors:  Andrea L Russo; Hyuk-Chan Kwon; William E Burgan; Donna Carter; Katie Beam; Xu Weizheng; Jie Zhang; Barbara S Slusher; Arnab Chakravarti; Philip J Tofilon; Kevin Camphausen
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

5.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Authors:  Nicholas C Turner; Christopher J Lord; Elizabeth Iorns; Rachel Brough; Sally Swift; Richard Elliott; Sydonia Rayter; Andrew N Tutt; Alan Ashworth
Journal:  EMBO J       Date:  2008-04-03       Impact factor: 11.598

6.  ATM activation and signaling under hypoxic conditions.

Authors:  Zuzana Bencokova; Muriel R Kaufmann; Isabel M Pires; Philip S Lecane; Amato J Giaccia; Ester M Hammond
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

Review 7.  Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

Authors:  Robert G Bristow; Richard P Hill
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

8.  Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Authors:  Shivaani Kummar; Robert Kinders; Martin E Gutierrez; Larry Rubinstein; Ralph E Parchment; Lawrence R Phillips; Jiuping Ji; Anne Monks; Jennifer A Low; Alice Chen; Anthony J Murgo; Jerry Collins; Seth M Steinberg; Helen Eliopoulos; Vincent L Giranda; Gary Gordon; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James H Doroshow
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

9.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Authors:  Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  85 in total

1.  Anticancer drugs: Expanding the horizons of PARP inhibitors.

Authors:  Teresa Villanueva
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Expanding the horizons of PARP inhibitors.

Authors:  Teresa Villanueva
Journal:  Nat Rev Cancer       Date:  2010-12       Impact factor: 60.716

3.  Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins.

Authors:  Susan E Scanlon; Peter M Glazer
Journal:  Mol Cancer Res       Date:  2014-03-31       Impact factor: 5.852

Review 4.  Pharmacological methods to transcriptionally modulate double-strand break DNA repair.

Authors:  Alanna R Kaplan; Peter M Glazer
Journal:  Int Rev Cell Mol Biol       Date:  2019-12-18       Impact factor: 6.813

5.  Ancestral gene regulatory networks drive cancer.

Authors:  Kimberly J Bussey; Luis H Cisneros; Charles H Lineweaver; Paul C W Davies
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

Review 6.  DNA repair dysregulation from cancer driver to therapeutic target.

Authors:  Nicola J Curtin
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

Review 7.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

8.  Stress-Induced Mutagenesis: Implications in Cancer and Drug Resistance.

Authors:  Devon M Fitzgerald; P J Hastings; Susan M Rosenberg
Journal:  Annu Rev Cancer Biol       Date:  2017-03

9.  New paradigms and future challenges in radiation oncology: an update of biological targets and technology.

Authors:  Stanley L Liauw; Philip P Connell; Ralph R Weichselbaum
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

Review 10.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.